ADVERTISEMENT
ADVERTISEMENT
polyneurophathy
RNA Interference Drug Excels in Clinical Trials to Treat Rare Disorder
Katarina Zimmer | Nov 3, 2017 | 2 min read
If approved, patisiran will be the first RNAi therapeutic on the market. 
ADVERTISEMENT